Monday, March 28, 2016

ValueAct Pays a Price for Its Supporting Role at Valeant by Unknown Author


By Unknown Author

ValueAct deserves credit — or blame — for virtually everything that happened to Valeant Pharmaceuticals over nearly the last decade.

Published: March 29, 2016 at 12:00AM

from NYT Business Day http://ift.tt/1SifQy6



from WordPress http://ift.tt/1oi8na3
via Hadi Aboukhater
Posted by at
Labels: , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)